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Summary points
• The current United States opioid overdose crisis is a complex, multifaceted, public
health emergency that urgently requires the implementation of evidence-based primary,
secondary, and tertiary preventive interventions. We develop a typology of the stigma
related to opioid use, showing how multiple dimensions of stigma continue to funda-
mentally hinder the response to the crisis.
• Public stigma is driven by stereotypes about people with opioid use disorders, such as
their perceived dangerousness or perceived moral failings, which translate into negative
attitudes toward people with opioid use disorders.
• Enacted stigma describes the behavioral manifestations of public stigma, including dis-
crimination and social distancing. Public and enacted stigma, in turn, lead to delivery of
suboptimal care and undermine access to treatment and harm reduction services.
• Public stigma and enacted stigma can become structural stigma when they become
encoded in cultural norms, laws, and institutional policies. Collectively, these forms of
stigma run at cross purposes to—and reduce public support for—public health–oriented
policies to address the opioid overdose crisis.
• When people with opioid use disorders internalize or anticipate the public stigma
attached to their illness, maladaptive behaviors (e.g., disengagement from care) leading
to poorer health outcomes may occur.
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• Each of these dimensions of stigma (structural, public, enacted, internalized, and antici-
pated) serve to reinforce each other, resulting in poorer health outcomes even as the epi-
demiology of opioid overdose mortality continues to change.
• These dimensions of stigma must be overcome to facilitate the requisite policy and pro-
grammatic changes needed to effectively address the opioid overdose crisis.
Introduction
The current US opioid overdose crisis is a public health emergency. The age-adjusted mortality
rate due to drug overdose more than tripled from 1999 to 2017 [1]. In recent years, the largest
increases in drug overdose mortality were observed for drug overdose deaths involving non-
pharmaceutical fentanyl, which increased by an average of 71% per year in 2013–2017 [1–4],
whereas overdose deaths involving prescription opioids and heroin have remained steady [5].
Concomitant with the rapid expansion in the magnitude of the opioid overdose crisis is an
expansion in its scope, with increasingly syndemic [6] involvement of cocaine and psychosti-
mulants [7–10].
There are multiple, interrelated, and deeply rooted social and economic determinants of
the US opioid overdose crisis, none of which are likely to provide a sufficient explanation for
the crisis when considered in isolation [11–17]. Although the epidemiology of opioid use and
opioid use disorders (OUDs) has changed over time, the stigma attached to opioid use has
endured [18]. Stigma is defined as a process wherein people with a particular social identity
are labeled, stereotyped, and devalued, unfolding within the context of unequal and often pre-
existing power relations, leading to discriminatory behavior against people with the stigma-
tized identity [19–21] (Box 1). Its persistence and its persistent effects on health are consistent
with its conceptualization as a “fundamental cause” of population health inequities across mul-
tiple social and physical health outcomes [22,23]. In the following discussion, we describe how
these multiple dimensions of stigma are a fundamental hindrance to the response to the US
opioid crisis.
The US opioid overdose crisis response: Multiple levels of
prevention needed
Given the complexity of the US opioid overdose crisis, an effective response will require a mul-
ticomponent portfolio of public health, social, and economic policy interventions to address
its social and structural determinants [11–17]. Health system interventions will also be neces-
sary to implement primary, secondary, and tertiary prevention of opioid overdoses [37]. First,
exposure to opioid use among opioid-naive patients should be minimized (primary preven-
tion). Second, among those exposed to opioids, nonmedical use of prescription opioids and
the incidence of OUDs must be reduced (secondary prevention). Third, expanded evidence-
based treatment for OUDs is needed so that people with existing OUDs can achieve sustained
remission, while the harms of ongoing opioid use (e.g., overdose) must be reduced for people
who cannot, or do not choose to, achieve sustained remission (tertiary prevention). In combi-
nation, these preventive interventions will address what Humphreys and Pollack [38] have
referred to as the “stock” and “flow” of the crisis: treatment and harm reduction for people
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already diagnosed with OUDs while simultaneously reducing the number of people with new
diagnoses.
One component of primary and secondary prevention is promoting cautious and thought-
ful opioid prescribing. People who are exposed to opioids—including prescribed opioids—are
at increased risk of long-term use and of developing OUDs [39–41]. Surveys of people with
OUDs often identify prescription opioids as the initiating opioid [42]. Thus, the importance of
the admonition to “keep opioid-naive patients opioid naive” (p. 1454) [43] cannot be over-
stated. Other strategies to support primary and secondary prevention have been discussed
extensively: reducing incautious and long-term opioid prescribing; preventing diversion; and
identifying patients who may be at risk for, or who have already developed, OUDs [44–46].
Given current trends, however, prescribing-focused interventions alone will be insufficient
to address the crisis. Opioid prescribing has already been in a nearly decade-long decline [47–
49]. There is also evidence that the incidence of initial opioid prescriptions for opioid-naive
patients has declined [50]. Despite these favorable trends, drug overdose mortality has contin-
ued to increase [1], with nonpharmaceutical fentanyl and its analogues increasingly associated
with drug overdose deaths [1–5]. Thus, a singular focus on physician prescribing of opioids, to
the exclusion of other prevention efforts, is unlikely to improve outcomes for those engaging
in nonmedical use of opioids (e.g., nonpharmaceutical fentanyl) [51,52].
Tertiary prevention should focus on expanding evidence-based treatment of OUDs and
reducing the harms of ongoing opioid use. Gold-standard, first-line treatment of OUDs con-
sists of opioid agonist medication (methadone) or partial agonist medication (buprenorphine)
Box 1. Typology of the stigma related to opioid use.
• Public stigma [24] is driven by stereotypes about people with OUDs [18], such as their
perceived dangerousness [25,26] or perceived moral failings [27], which translate into
negative attitudes.
• Anticipated stigma occurs when people with a stigmatized identity are subjectively
aware of such negative attitudes and develop expectations of being rejected were their
stigmatized (and potentially hidden) identities to become known [28]. Among people
who do not have the stigmatized identity, perceived stigma refers to subjective aware-
ness of negative attitudes and expectations of rejection were a hypothetical stigmatized
identity to become known.
• Internalized stigma results when people with a stigmatized identity come to accept
their devalued status as valid, thereby adopting for themselves the prevailing negative
attitudes embedded in public stigma [29,30].
• Enacted stigma describes the behavioral manifestations of public stigma, including dis-
crimination and social distancing [31,32].
• Family members and friends may experience all of these forms of stigma as a result of
their affiliation with people with OUDs, a phenomenon described as courtesy stigma
[21].
• Structural stigma refers to the totality of ways in which societies constrain those with
stigmatized identities through mutually reinforcing institutions, norms, policies, and
resources [33–36].
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[53]. Psychosocial interventions can also be effective when offered in conjunction with medi-
cation [54]. Yet only a minority of people with OUDs receive treatment of any kind, even after
nonfatal overdose [55,56]. This underuse represents a missed public health opportunity, given
the well-established effectiveness of opioid agonist treatment in reducing mortality [55,57].
Evidence-based harm reduction strategies for people with refractory OUDs include access to
sterile injection equipment to reduce secondary transmission of HIV and hepatitis C [58–60],
supervised consumption facilities [61] and supervised treatment with diacetylmorphine (her-
oin) [62] to reduce overdose risk, and expansion of overdose education and naloxone distribu-
tion to reduce the case-fatality rate of opioid overdoses when they do occur [63–65].
Stigma as a fundamental hindrance to the US opioid overdose
crisis response
Public and enacted stigma
Negative attitudes toward people with OUDs undermine secondary prevention responses.
People whose chronic noncancer pain syndromes have led to their physiological dependence
on prescription opioid medications may be marked with the same labels as people with OUDs
(e.g., morally weak, “addicts”) and experience difficulties obtaining care [66,67]. Healthcare
professionals’ stigmatizing beliefs [68] can lead to provision of suboptimal care, a form of
enacted stigma that reduces patients’ engagement with drug treatment [69–71]. In some
instances, these suboptimal care patterns may extend to maintaining overly rigid and nonbe-
neficent care policies, lacking respect for patient autonomy, and deploying punitive care termi-
nations in response to policy violations (e.g., smoking) or positive urine toxicology screening
[66,70]. In the 3 years since the US Centers for Disease Control and Prevention published its
new opioid-prescribing guideline [72], stigma enactments have included the imposition of
rigid dosage or duration caps or initiation of noncollaborative tapers with established patients,
escalating potential harms and transition to nonprescription opioids [73–78]. Enacted stigma
has also been directly associated with nonfatal overdose [79].
Tertiary prevention is compromised when the stigma attached to OUDs affects access to
treatment and harm reduction services. Among physicians who have obtained the US Drug
Enforcement Agency (DEA) waiver to prescribe buprenorphine [80], most are not prescribing
at capacity [81–83]; of these, many express little interest in taking on patients to reach capacity
[84]. This gap in treatment access may reflect provider distancing from patients stereotyped as
“difficult,” dangerous, or being involved in criminalized behaviors [85,86]. Other providers
may wish to avoid the legal scrutiny associated with being a considered a “pill mill” (e.g., DEA
audits) [87] or to avoid the courtesy stigma attached to caring for patients with OUDs [86,88].
Stigma has also undermined the wider distribution of overdose education and naloxone in the
community. Specific challenges include anticipated stigma [89], concerns about moral hazard
[90–92], or ignorance about state legislation related to naloxone prescribing or dispensing
[93,94]. Most states have passed “Good Samaritan laws” to limit criminal liability for bystand-
ers who provide or summon aid when witnessing an overdose incident [95], but the street-
level effectiveness of such legislation may be limited by anemic implementation and punitive
signaling by criminal law and law enforcement, including high-profile “drug-induced homi-
cide” prosecutions, loss of housing, and other legal repercussions [96,97].
Structural stigma
Public and enacted stigma can become structural stigma when they become encoded in cul-
tural norms, laws, and institutional policies. The effects of structural stigma on undermining
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treatment of OUDs can be observed in how care is financed and delivered. Treatment is gener-
ally covered by state Medicaid programs [98], but prior authorization requirements and arbi-
trary lifetime treatment limits impose significant barriers to care [99–102], and many
physicians who have obtained the waiver to prescribe buprenorphine do not accept third-
party payments [103–105]. The 2010 Patient Protection and Affordable Care Act, among its
many functions, sought to transform substance use treatment financing and delivery by man-
dating that effective treatments for substance use disorders be covered by third-party payers
and integrated into mainstream healthcare systems [106,107]. However, the Affordable Care
Act remains under threat, with attendant implications for the US opioid overdose crisis
response [108]. Even where treatment is covered, treatment availability is commonly under-
mined by exclusionary zoning practices (that are themselves the product of public stigma
[109,110]), further eroding engagement in care [111]. Concerns about treatment access are
exacerbated in rural settings [112].
Other stigmatizing polices affect the health of people with OUDs in ways that are unrelated
to treatment. Laws criminalizing the possession and distribution of certain substances codify
stigma through both normative and instrumental pathways [97]. Many transplant centers con-
sider OUDs, chronic opioid use, or opioid agonist treatment to be a relative contraindication
to proceeding with transplantation [113–115]. Similarly, people with a history of injection
drug use, or people on opioid agonist treatment (irrespective of injection drug use history), are
routinely excluded from receiving post-acute care in skilled nursing facilities [116] or paren-
teral antimicrobial therapy in outpatient settings [117,118]. Physicians identified as having
OUDs who are required to enroll in physician health programs are often required to adhere to
abstinence-only approaches and discontinue opioid agonist treatment as a condition of main-
taining professional licensure [119]. Taken together, these types of policies and related deci-
sion-making not only reinforce the ways in which people with OUDs are treated separately
from others but also implicitly classify people with OUDs as being unworthy of investment
and undeserving of treatment—thereby potentially having direct effects on health outcomes.
More generally, the language used to frame the crisis can influence norms about OUDs and
about people with OUDs among policymakers and their constituents, directly affecting the
policy levers that are brought to bear on the US opioid overdose crisis response. Everyday use
of stigmatizing language negatively influences attributions of responsibility and increases sup-
port for punitive judgments (e.g., “substance abuser” [120]) or devalues evidence-based treat-
ment of OUDs (e.g., “medication-assisted treatment” [121]). News coverage of the US opioid
overdose crisis has inadequately emphasized treatment [122,123] and has instead largely
framed the crisis as a criminal justice issue [124], particularly in ways that are racially disparate
[125]. The very use of the moniker “epidemic” to describe the overdose crisis invokes isolation,
quarantine, vector control, and other measures befitting infectious disease control but that are
poorly calibrated for responding to the multifactorial opioid overdose crisis [97]. Language
matters, because the judicious use of frames can shift public stigma [122,123], which can then
become encoded structurally in the lack of public support for public health–oriented policies
to address the opioid overdose crisis [126–131].
Internalized and anticipated stigma
When people with OUDs internalize or anticipate the public stigma attached to their illness,
maladaptive behaviors leading to poorer health outcomes may occur [132,133]. Among people
with OUDs, internalized stigma has been associated with psychological distress and poorer
quality of life [134–136], continued substance use [137], and reduced engagement with sub-
stance use treatment [138]. Anticipated stigma has also been associated with psychological
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distress [135,139] and reduced engagement in care [71,140–142]. In one nationally representa-
tive study of patients attending Health Resources and Services Administration health centers,
stigma was one of the most commonly reported reasons for not engaging in substance use
treatment [143]. The effects of internalized and anticipated stigma on treatment engagement
can be especially pronounced in rural areas and small communities where treatment providers
and their staff have multiple or overlapping relationships, thereby heightening concerns about
boundary violations or breaches of confidentiality [144].
For people with OUDs who do initiate treatment, continued adherence and retention in
care are needed to optimize outcomes. Longitudinal studies have consistently found that long-
term retention in buprenorphine treatment is poor, with only one-third retained in care at 2
years [145–147]. No studies have directly linked stigma to retention in care for opioid agonist
treatment, but among persons with other stigmatized conditions like HIV, stigma has been
found to be a consistently strong correlate of treatment adherence, retention in care, and treat-
ment outcomes [148,149].
Finally, the organization of treatment delivery itself can be stigmatizing to patients. Opioid
treatment programs providing methadone—and the supervision, monitoring, and restrictive
dispensing policies involved—are often experienced as degrading and humiliating [150–154].
Patient preferences for buprenorphine over methadone are routinely couched in terms of
avoiding the stigma of methadone use [151,155]. These aspects of treatment delivery are them-
selves a product of stigma (i.e., are informed by negative stereotypes applied to people with
OUDs) and are not necessary features of treatment itself [152].
Considerations for health disparity populations
People with OUDs who are incarcerated or who have recently been released from incarcera-
tion have a particularly urgent need for evidence-based treatment. Detoxification during incar-
ceration without linkage to treatment after release increases the risk of overdose substantially
[156–158]. However, few receive treatment during incarceration or are linked to treatment
after release [159–161]. This undertreatment of people with OUDs who also have a history of
involvement with the criminal justice system, often motivated by stigma [162], represents a
missed public health opportunity given the well-established effectiveness of opioid agonist
treatment in reducing recidivism [163] and mortality [164–166].
One of the most pernicious examples of the interactions between structural stigma, public
stigma, and enacted stigma can be observed in the racialized drivers of the US opioid overdose
crisis and of the policy and programmatic response to the crisis. Because of racial disparities in
receipt of opioid analgesia to treat acute pain [167] and treatment discontinuation following
aberrant urine drug-test results [168], blacks (compared with whites) were comparatively less
affected by the “second wave” of opioid-involved drug overdose deaths driven largely by the
natural/semisynthetic prescription opioids being readily prescribed by physicians influenced
by national clinical guidelines for assessment and treatment of pain [15]. However, with
increasing nonmedical use of prescription opioids and use of nonprescription opioids among
whites, news coverage about the opioid overdose crisis in suburban or rural white communi-
ties often features sympathetic, etiological narratives—whereas such accounts are typically
missing in coverage of the opioid overdose crisis among blacks and Latinos [125]. This selec-
tive stigmatization evokes the racialization of crack cocaine, racially disparate federal prosecu-
tions for crack (versus powder) cocaine, and disproportionately harsh federal sentencing of
blacks that continue to have reverberating impacts in the present day [169,170]. The racializa-
tion of OUDs has resulted in a treatment and prevention approach among blacks that is char-
acterized by overcriminalization and reliance on heavily regulated delivery of opioid agonist
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treatment segregated from traditional healthcare systems (i.e., daily dosing at community
methadone clinics), whereas treatment and prevention among whites has become increasingly
medicalized and addressed through office-based care [171,172]. In recent years, the burden of
the opioid overdose crisis has disproportionately increased among blacks compared with
whites [2]. Yet blacks receiving chronic prescription opioid treatment are more likely than
whites to experience dose tapers [173], buprenorphine treatment remains largely concentrated
among whites and in areas with higher proportions of white residents [174,175], and blacks
who are able to access treatment are less likely to be successfully retained in care [146].
Addressing stigma to support the US opioid overdose crisis response
The response to the US opioid overdose crisis urgently requires the implementation of evi-
dence-based primary, secondary, and tertiary prevention. The policy changes that are needed
to support these interventions are well understood and have been discussed extensively
[80,176–178]. Yet the stigma attached to OUDs remains a fundamental hindrance to the crisis
response. Multiple dimensions of stigma (structural, public, enacted, internalized, and antici-
pated) that are rooted in intersecting social categories serve to reinforce each other, resulting
in poorer health outcomes even as the epidemiology of opioid overdose mortality continues to
change. Stigma influences everyday attitudes, agenda setting, and policy-making. Stigma com-
promises the financing of care for OUDs, shapes the distribution of access to care, and
impinges upon care delivery. Stigma even undermines the health of people with OUDs in ways
that have nothing to do with the treatment of OUDs.
What is less well understood is how the stigma-related barriers to these requisite policy and
programmatic changes can be overcome, either directly or indirectly. Direct interventions to
reduce public and enacted stigma may take the form of persuasive communication or educa-
tional interventions—such as those deployed through mass media campaigns, law enforce-
ment training [179], or schools—designed to improve understanding about the causes of and
evidence-based treatments for OUDs. However, the sustained, long-term impacts of such
interventions on stigma are unknown [180]. To improve care within healthcare delivery set-
tings specifically, direct educational interventions may involve curricular changes at the level
of undergraduate [181], graduate [182], or continuing [183] medical education. The specific
educational content packaged within such interventions should be selected carefully. Educa-
tion about the biomedical foundation of OUDs, for example, may not necessarily have the
desired effects on stigma [184,185]. Contact interventions also hold promise for stigma reduc-
tion [186], but, as with educational interventions, their long-term effects remain unknown
[187]. Finally, for people with OUDs, direct interventions to reduce internalized and antici-
pated stigma might draw on approaches from cognitive behavioral therapy [188] or acceptance
and commitment therapy [189].
Indirect interventions might target institutions instead of individuals. For example, the mass
media plays a central role in shaping our culture and therefore may represent a critical lever for
influencing how multiple levels of stigma translate into specific behaviors and policies. Some print
media organizations have issued professional guidance about reducing the use of stigmatizing
frames in reporting about the opioid overdose crisis [190]. As another example, the “Changing
the Narrative” project at Northeastern University (https://www.changingthenarrative.news) aims
to reduce stigma and improve the accuracy of media portrayals, using various strategies such as
promotion of style guides, “detailing” to journalists and editors, and social media monitoring and
outreach. If disseminated nationally, similar to the Australian government’s support of the Mind-
frameMedia andMental Health Project [191], the impacts on public stigma could be substantial
[123,126,129,192,193]. Some academic journals [194,195] and academic societies [196] have
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adopted similar guidelines. Broadcast media, rather than conditioning people to be fearful of per-
sons with OUDs [197], can potentially reduce public stigma by portraying people with OUDs in
ways that provide viewers with insight into the structural factors surrounding their use of opioids.
However, as with print media, guidance on film and television portrayals fall under the purview
of multiple trade groups and companies, and the levers for intervention are likely to be similarly
diffuse.
The extent to which these direct or indirect interventions will successfully translate into
changes in structural stigma, including agenda setting and policy change, remains unknown.
Elected officials’ voting behavior and successful policy enactment are contingent upon numer-
ous factors [198–200], of which public stigma is only one. Moreover, the systematic disenfran-
chisement of people with past criminal convictions is one of the most spiteful barriers to policy
reform, because it strips voting rights from people whose behaviors were criminalized by the
very laws that they are now powerless to change [97]. Thus, there will remain a need for civil
society organizations and activist initiatives to have a central role in influencing governmental
responses to the overdose crisis. More research is needed to understand the causal pathways
through which stigma acts so that interventions targeting these mechanisms can be deployed
to enhance the opioid overdose crisis response. Until the stigma of OUDs is addressed, it will
continue to hinder implementation of these interventions, exacerbating existing population
health inequalities.
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